Skip to search formSkip to main contentSkip to account menu

XL 184

Known as: XL-184, XL184 cpd 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

cabozantinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract 2351: AXL and c-MET cross-talk in the regulation of PD-L1 expression on renal cancer cells
Purpose: The purpose of this research is to study the cross-talk between receptor tyrosine kinases (RTKs) c-MET and AXL in renal… 
2015
2015
Abstract 5497: Cabozantinib eradicatesde novocastrate-resistant PTEN/p53 deficient murine prostate cancer via activation of neutrophil-mediated anti-tumor innate immunity
The majority of kinase inhibitors in cancer clinical trials have been evaluated in the context of cell autonomous induction of… 
2014
2014
Abstract 3459: SRC family kinase FYN promotes MET tyrosine kinase activation, epithelial to mesenchymal transition and metastasis in human prostate cancer
Introduction: FYN is a Src family kinase (SFK) member that has been shown to be upregulated in human prostate cancer tissues and… 
Review
2013
Review
2013
Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer.
Mutation detection in samples from thyroid cancer with the addition of BRAF mutation, and also the detection of RAS, RET/PTC, and… 
Review
2012
Review
2012
Novel molecular targeted therapies for refractory thyroid cancer
The incidence of thyroid cancer continues to increase and this neoplasia remains the most common endocrine malignancy. No… 
2012
2012
Abstract IA11: Cabozantinib (XL-184) and prostate cancer: Preclinical and clinical profile of a novel agent
The evolving understanding of the biology of prostate cancer has fueled therapeutic research with agents targeting androgen… 
Review
2011
Review
2011
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
The prognosis of almost all thyroid cancers is good, but some patients have indications for these molecularly targeted drugs… 
Review
2010
Review
2010
Targeted therapy for thyroid cancer: An updated review of investigational agents.
The treatment of thyroid cancer is evolving. The molecular mechanisms of carcinogenesis for many thyroid cancers have been… 
2008
2008
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2006
2006
Gateways to clinical trials.
101M, 12B75; ABT-869, Agomelatine, Alvocidib hydrochloride, Amb a 1 ISS-1018, AMG-386, Andolast, AP-23573, Arsenic trioxide, ATI… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)